Dr. Peng Jiao, President and CEO of BiBo Biopharma, a biologics CDMO, delivered a report on the 4th Revolutionary Wave of Biologics Manufacturing at the 25th Annual Conference of SAPA-NE (Sino-American Pharmaceutical Association, New England) at Marriot in Cambridge, MA on June 3, 2023.
Dr. Peng Jiao detailed BiBo Biopharma’s leading role for the incoming 4th wave of biologics manufacturing. Biologics manufacturing has undergone three waves since the 1980s, driven by biologics technological innovation and socio-economic development. These three waves of biologics manufacturing differentiate themselves by their technology platform, facility capacity scale, and mode of production. With the rise of the global biologics market and growing demand for protein-based drugs, the problem of capacity shortages in biologics manufacturing has become increasingly prominent. Large-scale commercial production based on CDMOs has become an industry trend. These factors entail a 4th wave of biologics manufacturing, and as a CDMO featuring 30,000-liter bioreactor ultra-large-scale technology in a million-liter total capacity MEGA factory, BiBo Biopharma is uniquely prepared to transform the biologics manufacturing market with its disruptive PanFlex® technology.Through years of accumulating profound technology in biologics manufacturing, BiBo is now the first in the world to have established 30,000 liters of ultra-large scale mammalian cell production technology. Empowered by its unique PanFlex® system, BiBo is developing the next generation Mega-factory with a total planned capacity of over 1.2 million liters at ½ time and ½ cost. Leading the 4th wave of biological manufacturing, BiBo is expected to shape the future of global biologics manufacturing for the benefit of patients worldwide.SAPA-NE is a SAPA chapter located in the New England region of the U.S. Founded in 1998, the SAPA-NE Annual Conference is a well-established platform for industry and academic leaders to share their knowledge, experience, and perspectives on science, technology, and business and make a positive impact in the life sciences community.
About BiBo:
Started in Boston in 2015, BiBo kicked off its Shanghai R&D center in 2017 and launched three GMP manufacturing plants since then. As a full life-cycle, full spectrum CDMO, BiBo Biopharma established the world first and largest 30kL mammalian cell production line to ensure our clients gain a sufficient supply of biologics products at the most inexpensive cost. With the revolutionary PanFlex®, BiBo Biopharma is actively building a new international CDMO industry standard with the goal of becoming a trusted third-party R&D and manufacturing partner for global clients.
